Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 167

9 diseases · 23 shared-gene connections
9 Diseases
27 Unique genes
0.235 Avg. similarity score
Hyper-ige syndrome Most-connected disease (7 links)
Log in to save this analysis

Save This Analysis

Disease Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Hyper-ige syndrome 7 7 1
Lymphoproliferative disorder of natural killer cells 7 7 1
STAT3-related early-onset multisystem autoimmune disease 7 7 1
hyper-IgE recurrent infection syndrome 1, autosomal dominant 7 7 1
Breast implant-associated anaplastic large cell lymphoma 5 5 6
Atrophy 4 4 10
Copper overload cirrhosis 4 4 11
Hyper-immunoglobulin e syndrome 4 4 3
Autoinflammation, immune dysregulation, and eosinophilia 1 1 1

Top shared genes (genes linked to 2+ member diseases)

Gene ⇵ Member diseases ⇵ Linked diseases
STAT3 8 / 9 Atrophy, Breast implant-associated anaplastic large cell lymphoma, Copper overload cirrhosis, hyper-IgE recurrent infection syndrome 1, autosomal dominant and 4 more
JAK1 2 / 9 Autoinflammation, immune dysregulation, and eosinophilia, Breast implant-associated anaplastic large cell lymphoma
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Pancreatic cancer
MAPK3, RPS6KB1, STAT3, JAK1, BRCA2, TP53, SMAD2, TGFB1
 KEGG 8 / 77 46.2× 3.96e-12 7.64e-10 ✓ sig.
Proteoglycans in cancer
MAPK3, RPS6KB1, STAT3, TP53, CASP3, HGF, MET, SMAD2, TGFB1, ITGB3
 KEGG 10 / 204 21.8× 1.05e-11 1.87e-9 ✓ sig.
Pathways in cancer
MAPK3, RPS6KB1, STAT3, JAK1, BRCA2, JAK2, TP53, CASP3, HGF, MET, SMAD2, TGFB1
 KEGG 13 / 533 10.8× 2.54e-11 4.14e-9 ✓ sig.
Th17 cell differentiation
AHR, MAPK3, STAT3, JAK1, JAK2, SMAD2, TGFB1, IL6ST
 KEGG 8 / 109 32.6× 6.83e-11 1.02e-8 ✓ sig.
EGFR tyrosine kinase inhibitor resistance
MAPK3, RPS6KB1, STAT3, JAK1, JAK2, HGF, MET
 KEGG 7 / 80 38.9× 3.55e-10 4.51e-8 ✓ sig.
MAPK3 (ERK1) activation
MAPK3, JAK1, JAK2, IL6ST
 Reactome 4 / 10 178× 4.21e-9 4.07e-7 ✓ sig.
Interleukin-27 signaling
STAT3, JAK1, JAK2, IL6ST
 Reactome 4 / 11 162× 6.61e-9 6.10e-7 ✓ sig.
Interleukin-6 signaling
STAT3, JAK1, JAK2, IL6ST
 Reactome 4 / 11 162× 6.61e-9 6.10e-7 ✓ sig.
Interleukin-35 Signalling
STAT3, JAK1, JAK2, IL6ST
 Reactome 4 / 12 148× 9.90e-9 8.64e-7 ✓ sig.
MET activates STAT3
STAT3, HGF, MET
 Reactome 3 / 3 445× 1.01e-8 8.81e-7 ✓ sig.
Gastric cancer
MAPK3, RPS6KB1, TP53, HGF, MET, SMAD2, TGFB1
 KEGG 7 / 150 20.8× 2.97e-8 2.27e-6 ✓ sig.
Colorectal cancer
MAPK3, RPS6KB1, TP53, CASP3, SMAD2, TGFB1
 KEGG 6 / 87 30.7× 3.18e-8 2.41e-6 ✓ sig.
PI3K-Akt signaling pathway
MAPK3, RPS6KB1, JAK1, BRCA1, JAK2, TP53, HGF, MET, ITGB3
 KEGG 9 / 361 11.1× 5.27e-8 3.74e-6 ✓ sig.
Hepatitis B
MAPK3, STAT3, JAK1, JAK2, TP53, CASP3, TGFB1
 KEGG 7 / 163 19.1× 5.27e-8 3.74e-6 ✓ sig.
Hepatocellular carcinoma
MAPK3, RPS6KB1, TP53, HGF, MET, SMAD2, TGFB1
 KEGG 7 / 170 18.3× 7.04e-8 4.82e-6 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
interleukin-6-mediated signaling pathway
STAT3, JAK1, JAK2, IL6ST
 GO:0070102 4 / 16 173× 6.21e-9 1.13e-6 ✓ sig.
negative regulation of autophagy
MAPK3, RPS6KB1, STAT3, HGF, MET
 GO:0010507 5 / 73 47.4× 5.98e-8 7.87e-6 ✓ sig.
interleukin-11-mediated signaling pathway
STAT3, JAK1, IL6ST
 GO:0038154 3 / 7 297× 9.38e-8 1.14e-5 ✓ sig.
positive regulation of vascular endothelial growth factor production
STAT3, BRCA1, TGFB1, IL6ST
 GO:0010575 4 / 32 86.5× 1.21e-7 1.41e-5 ✓ sig.
cellular response to ionizing radiation
BRCA1, BRCA2, TP53, TGFB1
 GO:0071479 4 / 41 67.5× 3.37e-7 3.36e-5 ✓ sig.
positive regulation of gene expression
CLU, STAT3, BRCA1, TP53, ACTA2, SMAD2, TGFB1, ITGB3
 GO:0010628 8 / 504 11.0× 3.74e-7 3.66e-5 ✓ sig.
T-helper 17 cell lineage commitment
STAT3, JAK1, IL6ST
 GO:0072540 3 / 13 160× 7.62e-7 6.67e-5 ✓ sig.
growth hormone receptor signaling pathway via JAK-STAT
STAT3, JAK1, JAK2
 GO:0060397 3 / 15 138× 1.21e-6 9.66e-5 ✓ sig.
type II interferon-mediated signaling pathway
JAK1, JAK2, TP53
 GO:0060333 3 / 15 138× 1.21e-6 9.66e-5 ✓ sig.
cell population proliferation
STAT3, BRCA2, TP53, MKI67, SMAD2, TGFB1
 GO:0008283 6 / 263 15.8× 1.70e-6 1.26e-4 ✓ sig.
cytokine-mediated signaling pathway
SLC1A1, STAT3, JAK1, JAK2, IL6ST
 GO:0019221 5 / 145 23.9× 1.85e-6 1.35e-4 ✓ sig.
positive regulation of growth factor dependent skeletal muscle satellite cell proliferation
STAT3, JAK2
 GO:1902728 2 / 2 692× 2.01e-6 1.45e-4 ✓ sig.
cell surface receptor signaling pathway via JAK-STAT
STAT3, JAK1, JAK2, IL6ST
 GO:0007259 4 / 67 41.3× 2.49e-6 1.72e-4 ✓ sig.
response to X-ray
BRCA2, TP53, CASP3
 GO:0010165 3 / 19 109× 2.57e-6 1.75e-4 ✓ sig.
response to antibiotic
JAK1, JAK2, TP53
 GO:0046677 3 / 21 98.9× 3.52e-6 2.27e-4 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
Lymphoproliferative disorder of natural killer cells STAT3-related early-onset multisystem autoimmune disease 0.500 1 6.49e-5 2.34e-4 ✓ sig.
Hyper-ige syndrome STAT3-related early-onset multisystem autoimmune disease 0.500 1 6.49e-5 2.34e-4 ✓ sig.
Hyper-ige syndrome Lymphoproliferative disorder of natural killer cells 0.500 1 6.49e-5 2.34e-4 ✓ sig.
hyper-IgE recurrent infection syndrome 1, autosomal dominant Hyper-ige syndrome 0.500 1 6.49e-5 2.34e-4 ✓ sig.
hyper-IgE recurrent infection syndrome 1, autosomal dominant Lymphoproliferative disorder of natural killer cells 0.500 1 6.49e-5 2.34e-4 ✓ sig.
hyper-IgE recurrent infection syndrome 1, autosomal dominant STAT3-related early-onset multisystem autoimmune disease 0.500 1 6.49e-5 2.34e-4 ✓ sig.
Hyper-immunoglobulin e syndrome STAT3-related early-onset multisystem autoimmune disease 0.250 1 1.95e-4 5.28e-4 ✓ sig.
Hyper-immunoglobulin e syndrome Lymphoproliferative disorder of natural killer cells 0.250 1 1.95e-4 5.28e-4 ✓ sig.
Hyper-ige syndrome Hyper-immunoglobulin e syndrome 0.250 1 1.95e-4 5.28e-4 ✓ sig.
hyper-IgE recurrent infection syndrome 1, autosomal dominant Hyper-immunoglobulin e syndrome 0.250 1 1.95e-4 5.28e-4 ✓ sig.
Breast implant-associated anaplastic large cell lymphoma STAT3-related early-onset multisystem autoimmune disease 0.143 1 3.90e-4 8.52e-4 ✓ sig.
Breast implant-associated anaplastic large cell lymphoma Lymphoproliferative disorder of natural killer cells 0.143 1 3.90e-4 8.52e-4 ✓ sig.
Breast implant-associated anaplastic large cell lymphoma Hyper-ige syndrome 0.143 1 3.90e-4 8.52e-4 ✓ sig.
Breast implant-associated anaplastic large cell lymphoma hyper-IgE recurrent infection syndrome 1, autosomal dominant 0.143 1 3.90e-4 8.52e-4 ✓ sig.
Autoinflammation, immune dysregulation, and eosinophilia Breast implant-associated anaplastic large cell lymphoma 0.143 1 3.90e-4 8.52e-4 ✓ sig.
Atrophy hyper-IgE recurrent infection syndrome 1, autosomal dominant 0.091 1 6.49e-4 1.22e-3 ✓ sig.
Atrophy STAT3-related early-onset multisystem autoimmune disease 0.091 1 6.49e-4 1.22e-3 ✓ sig.
Atrophy Lymphoproliferative disorder of natural killer cells 0.091 1 6.49e-4 1.22e-3 ✓ sig.
Atrophy Hyper-ige syndrome 0.091 1 6.49e-4 1.22e-3 ✓ sig.
Copper overload cirrhosis hyper-IgE recurrent infection syndrome 1, autosomal dominant 0.083 1 7.14e-4 1.31e-3 ✓ sig.
Copper overload cirrhosis STAT3-related early-onset multisystem autoimmune disease 0.083 1 7.14e-4 1.31e-3 ✓ sig.
Copper overload cirrhosis Lymphoproliferative disorder of natural killer cells 0.083 1 7.14e-4 1.31e-3 ✓ sig.
Copper overload cirrhosis Hyper-ige syndrome 0.083 1 7.14e-4 1.31e-3 ✓ sig.